NasdaqGS:NBIXBiotechs
Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio
Neurocrine Biosciences, ticker NasdaqGS:NBIX, held an official M&A call regarding Soleno Therapeutics.
The call focused on a potential transaction involving Soleno Therapeutics and its assets.
This development highlights a possible shift in Neurocrine’s business plans and portfolio priorities.
The M&A discussion represents a material event for current and prospective shareholders of NasdaqGS:NBIX.
Neurocrine Biosciences focuses on treatments for neurological and endocrine related disorders,...